Motta AAL, et al. - In eyes with diabetic macular edema (DME), researchers analyzed contrast sensitivity of intravitreal bevacizumab injections with optimizing glycemic control vs optimizing glycemic control (in combination with sham injections). For this prospective, interventional, masked, randomized controlled trial, 41 eyes of 34 patients with type 2 diabetes mellitus and DME with glycated hemoglobin (HbA1c) <11% received either intravitreal bevacizumab injection (Group 1) or sham injection (Group 2) at 0 and 6 weeks along with optimizing glycemic control. In type 2 diabetes patients with DME, the use of bevacizumab in combination with optimizing glycemic control results in earlier improvement of contrast sensitivity. However, the glycemic control optimization itself has also been shown to be effective at 12 weeks. The mean reduction in HbA1c levels in both groups was approximately 0.5% at 12 weeks.